Exploring the Role of Diagnostic Biochemistry

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 801

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Zagreb University School of Medicine, Zagreb, Croatia
Interests: clinical biochemistry; molecular diagnostics; genetics; epigenetics

E-Mail Website
Guest Editor
Clinical Department of Laboratory Diagnosis, Clinical Hospital Center Rijeka, Rijeka, Croatia
Interests: clinical biochemistry; health informatics; clinical laboratory science; laboratory analysis

Special Issue Information

Dear Colleagues,

Biochemical testing is used in clinical medicine to obtain biochemical information for the treatment of patients. Information can only be used effectively for clinical decision making if it is true and appropriate, and if the physician recognizes how important it is. Among other kinds of diagnostics, laboratory tests are included in almost 80% of clinical decisions. Therefore, patient safety in laboratory medicine must be thoroughly assured. It needs to be acknowledged as a guarantee against any potential mistakes in the total testing process. Biochemistry is therefore essential in the diagnosis and management of different disorders.

Prof. Dr. Daria Pašalić
Prof. Dr. Lidija Bilic-Zulle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • laboratory tests in diagnosis, prognosis, monitoring, and treatment
  • blood biomarkers in laboratory medicine
  • extravascular body fluid biomarkers in laboratory medicine
  • novel biomarkers in clinical biochemistry
  • evidence-based laboratory medicine
  • extra analytical phase and patient safety
  • quality assurance and management in laboratory medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1428 KiB  
Article
Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels
by Soon Kyu Lee, Soon Woo Nam, Jeong Won Jang and Jung Hyun Kwon
Diagnostics 2024, 14(5), 495; https://doi.org/10.3390/diagnostics14050495 - 25 Feb 2024
Viewed by 552
Abstract
The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (<2 log IU/mL) remain unclear. Of some 1661 consecutively enrolled [...] Read more.
The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (<2 log IU/mL) remain unclear. Of some 1661 consecutively enrolled patients newly treated with entecavir or tenofovir, we analyzed 852 patients who underwent serial HBsAg level checks every 6–12 months. The primary outcomes included long-term kinetics in HBsAg levels and the rate of functional cure and achieving low HBsAg levels. Over a mean 6.3-year follow-up, the functional cure rate was 2.28% (n = 19), and 12.9% (n = 108) achieved low HBsAg levels. A significant HBsAg level reduction was seen in the first treatment year (p < 0.05), with another stepwise decrease between year 6–7. These trends were pronounced in patients with chronic hepatitis and HBeAg-positivity compared to those with cirrhosis and HBeAg-negativity, respectively. Baseline HBsAg of ≤3 log IU/mL and the first-year HBsAg reduction were key predictors for both functional cure and low HBsAg levels (p < 0.05). In conclusion, our findings elucidate the stepwise reduction in quantitative HBsAg dynamics during high-potency NA therapy (entecavir or tenofovir) along with variations based on different conditions. We also underscore the significance of quantitative HBsAg titer in predicting functional cure and low-HBsAg levels. Full article
(This article belongs to the Special Issue Exploring the Role of Diagnostic Biochemistry)
Show Figures

Graphical abstract

Back to TopTop